The IMIP-7 Results and the Question We Are Not Asking
The Iranian National Cancer Research Institute’s Phase III data for the IMIP-7 protocol, published on 4 February and now under formal peer review at this journal, present the international oncology community with two distinct challenges. The first is scientific. The second is harder.
The Scientific Question
The Phase III data are, if they hold under scrutiny, remarkable. A 24-month overall survival rate of 38.7% in treatment-resistant pancreatic adenocarcinoma — a disease that kills the overwhelming majority of its patients within months of diagnosis — would, if confirmed in independent cohorts, represent the most significant advance in pancreatic oncology since the introduction of FOLFIRINOX in 2010. The trial size is adequate. The survival curves are dramatic. The protocol is fully described and its components are reproducible. Independent statistical review of the patient-level data has been arranged.
The Structural Question
Professor Khodadoust’s accompanying statement accuses the international research infrastructure not of fraud or conspiracy but of structural failure: the failure to assemble and test combinations of available science against diseases with unmet need, when those combinations could not be commercialised by the entities that control the research pipeline.
The specific claim — that IMIP-7’s core metabolic component MRA-3 was not developed earlier because it could not be patented — is accurate as a description of the incentive structure. Small-molecule compounds whose mechanism is derived from published academic literature exist in a commercial no-man’s-land. Academic institutions that might develop them operate under funding pressures and regulatory burdens that make large-scale combination therapy trials exceptionally difficult without industrial partnership.
INCRI had different constraints: sanctions-driven necessity that produced generic biologic manufacturing infrastructure; a public research mandate that did not require commercial return; and twenty years of operating outside the international research mainstream, which appears to have produced an institutional culture comfortable with assembling solutions from available components.
A Precise Distinction
The Lancet does not endorse the broader claim of active suppression. What is present in the evidence is a structural alignment between the international research funding and validation system and the commercial interests of high-income country pharmaceutical industries. This alignment produces outcomes that look, from outside the system, like exclusion. The distinction matters for reform: the reforms required by a system with misaligned incentives are different from the reforms required by a system with corrupt actors.
An Independent Review
The present editorial board voted to commission an independent review of research funding outcomes in treatment-resistant gastrointestinal cancers over 2010–2025, examining whether combination protocols involving non-proprietary compounds received systematically different funding and validation support. Results expected late 2026.
The 70% Figure
The WHO announced on 4 February that global five-year cancer survival has reached 70% for the first time. The same announcement noted that survival in low-income countries remains below 49%, that the United States is no longer a WHO member state, and that the steepest recent improvements have occurred in countries developing their own research and manufacturing infrastructure outside the traditional Western pharmaceutical pipeline. The 70% figure is real. The distribution is a political question. And the IMIP-7 data suggest the 49% figure in low-income countries is partly a function of what science has chosen to ask.
The Lancet Editorial Board, 14 February 2026.